

**FITC anti-human CD7**

**Catalog # / Size:** 2315520 / 100 tests  
2315515 / 25 tests

**Clone:** CD7-6B7

**Isotype:** Mouse IgG2a, κ

**Immunogen:** KG1a cell line


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** IV T-164

**Concentration:** Lot-specific




Human peripheral blood lymphocytes stained with mouse IgG2a, κ (MOPC-173) FITC and CD4 APC

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Human peripheral blood lymphocytes stained with CD7-6B7 FITC and CD4 APC

**Application References:** 1. Knapp W, *et al.* 1989. *Leucocyte Typing IV: White Cell Differentiation Antigens.* Oxford University Press.

**Description:** CD7 is a 40 kD type I transmembrane glycoprotein also known as gp40. It is a member of the immunoglobulin superfamily found on T cells, NK cells, thymocytes, hematopoietic progenitors, and monocytes (weakly). CD7 is also expressed on acute lymphocytic leukemia (ALL) and some acute myeloid leukemia (AML) cells. CD7 crosslinking induces a calcium flux in T lymphocytes, presumably as a result of cytoplasmic domain association with PI3-kinase. CD7 costimulation can induce cytokine secretion and modulate cellular adhesion.

**Antigen References:** 1. Barclay N, *et al.* 1993. *The Leucocyte Antigen FactsBook.* Academic Press Inc. San Diego.  
2. Stillwell R, *et al.* 2001. *Immunol. Res.* 24:31.  
3. Rabinowich H, *et al.* 1994. *J. Immunol.* 152:517.